Heather Preston | Managing Partner, Pivotal BioVentures

Heather-PrestonPrior to joining Pivotal BioVentures in July 2018, Dr. Preston spent 13 years as Partner & Managing Director at TPG Biotech. Previously, she spent two years at JP Morgan Partners where she focused on medical device and biotechnology venture capital investing. Prior to JP Morgan Partners, Dr. Preston was an Entrepreneur-in-Residence with New Enterprise Associates. She also spent five years at McKinsey & Co. in New York, where she was a leader of their pharmaceutical and medical products consulting practice. She advised large pharmaceutical companies and biotechnology companies on critical strategic issues such as R&D portfolio prioritization, M&A opportunities, new technology acquisitions, new product launches and product growth strategies.

Dr. Preston has an undergraduate degree in biochemistry from the University of London and a medical degree from the University of Oxford. Dr Preston completed a post-doctoral fellowship in molecular biology at the Dana Farber Cancer Institute, Harvard University and trained in Internal Medicine at the Massachusetts General Hospital and subspecialized in Gastroenterology and Hepatology at UCSF. During her academic medical career, she was the recipient of a Fulbright Scholarship, a Fulbright Cancer Research Scholarship, a Harlech Scholarship and a Science and Engineering Research Council Post-doctoral Fellowship Award

Dr. Preston co-founded Virobay Inc., a biotechnology company which is seeking to develop new therapies for the treatment of pain and auto-immune diseases. Dr. Preston currently serves on the board of directors of Albireo, Inc.; Alder BioPharmaceuticals, Inc. [ALDR]; Otonomy, Inc. [OTIC]; and Virobay, Inc. She previously served on the boards of Aptalis Pharma (acquired by Forest Labs in February 2014), Conventus, Vibrynt, VLST and Elevation Pharmaceuticals (acquired by Sunovion in September 2012) and is responsible for overseeing TPG Biotech’s investment in Par Pharmaceuticals.